404
Page Not Found
The page you're looking for doesn't exist or has been moved.
The page you're looking for doesn't exist or has been moved.
Trimi Medical Review Team
Clinical review workflow for GLP-1 safety, dosing, and access content
Team-based medical review process documented in Trimi's Medical Review Policy
Last reviewed: November 26, 2025
Medical Writers & Healthcare Professionals
Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.
Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.
Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.
Retatrutide produced up to 24% weight loss in Phase 2 trials. See dose-response data, comparison with semaglutide and tirzepatide, timeline projections, and FDA approval outlook.
Detailed comparison of retatrutide vs tirzepatide: 24.2% vs 22.5% weight loss, mechanism differences, side effects, cost projections, and whether to wait or start now.
Side-by-side comparison of retatrutide, tirzepatide, and semaglutide: mechanisms, weight loss data, side effects, dosing, cost, and availability in 2026.
FDA approved oral Wegovy (semaglutide 50mg tablet) for weight loss in 2026. Review covers clinical trial results (~15% body weight loss), dosing, side effects, cost ($1,000–$1,500/mo), and affordable injectable alternatives.